RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Artelo Biosciences Stock

Artelo Biosciences Stocks 2024

Artelo Biosciences Stocks

2.96 M

Ticker

ARTL

ISIN

US04301G2012

WKN

A2PNJU

In 2024, Artelo Biosciences had 2.96 M outstanding stocks, a 0% change from the 2.96 M stocks in the previous year.

The Artelo Biosciences Stocks history

YEARNUMBER OF STOCKS (undefined USD)
2026e2.96
2025e2.96
2024e2.96
20232.96
20222.83
20211.25
20200.25
20190.14
20180.68
20170.58
20160.51
20150.43
20140.2
20130.2

Artelo Biosciences shares outstanding

The number of shares was Artelo Biosciences in 2023 — This indicates how many shares 2.96 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Artelo Biosciences earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Artelo Biosciences's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Artelo Biosciences’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Artelo Biosciences's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Artelo Biosciences Aktienanalyse

What does Artelo Biosciences do?

Artelo Biosciences Inc is an innovative biopharmaceutical company specializing in the research and development of new therapies for the treatment of cancer and inflammatory diseases. The company was founded in 2011 and is headquartered in Manchester, UK, with a branch office in San Diego, USA. Artelo Biosciences Inc began with the discovery of new drug candidates based on the body's endocannabinoid system, which plays a crucial role in regulating various physiological processes such as pain, inflammation, mood, and appetite. The company's business model is based on identifying and researching new drug candidates based on the endocannabinoid system, as well as developing and marketing new therapies for the treatment of cancer and inflammatory diseases. Artelo Biosciences Inc operates in various sectors, including cancer therapy, inflammation inhibition, and neurological disorders. In cancer therapy, the company focuses on the development of new drugs for the treatment of solid tumors, particularly triple-negative breast cancer (TNBC), a highly aggressive type of cancer for which there are currently limited therapy options. Artelo Biosciences Inc has several promising drug candidates, including ART27.13, a synthetic cannabinoid receptor agonist that has shown in preclinical studies to inhibit the growth of TNBC cells. In inflammation inhibition, Artelo Biosciences Inc focuses on the development of new drugs for the treatment of diabetes, obesity, and inflammatory bowel diseases. The company has several promising drug candidates, including ART26.12, a synthetic endocannabinoid receptor agonist that has shown in preclinical studies to reduce inflammation in the intestine and improve insulin sensitivity. In neurological therapy, Artelo Biosciences Inc focuses on the development of new drugs for the treatment of anxiety and pain. The company has several promising drug candidates, including ART12.11, a synthetic endocannabinoid receptor agonist that has shown in preclinical studies to reduce anxiety and inhibit pain perception. Artelo Biosciences Inc closely collaborates with leading academic institutions and research centers to develop and test its drug candidates. The company has a strong research and development department composed of highly qualified scientists and clinicians. It also has an effective licensing and marketing strategy to bring its products to market. In summary, Artelo Biosciences Inc is an innovative biopharmaceutical company specializing in the research and development of new therapies for the treatment of cancer and inflammatory diseases. The company's business model is based on identifying and researching new drug candidates based on the endocannabinoid system, as well as developing and marketing new therapies. The company operates in various sectors, including cancer therapy, inflammation inhibition, and neurological disorders. Artelo Biosciences Inc has its own patents and licenses, a strong research and development department, and an effective licensing and marketing strategy to bring its products to market. Artelo Biosciences ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating Artelo Biosciences's Shares Outstanding

Artelo Biosciences's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Artelo Biosciences’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Artelo Biosciences’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Artelo Biosciences’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Artelo Biosciences stock

How many stocks are there of Artelo Biosciences?

The current number of stocks of Artelo Biosciences is 2.96 M undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of Artelo Biosciences are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of Artelo Biosciences evolved in recent years?

The number of shares of Artelo Biosciences has increased by 0% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. Artelo Biosciences as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of Artelo Biosciences?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does Artelo Biosciences pay?

Over the past 12 months, Artelo Biosciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Artelo Biosciences is expected to pay a dividend of 0 USD.

What is the dividend yield of Artelo Biosciences?

The current dividend yield of Artelo Biosciences is .

When does Artelo Biosciences pay dividends?

Artelo Biosciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Artelo Biosciences?

Artelo Biosciences paid dividends every year for the past 0 years.

What is the dividend of Artelo Biosciences?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Artelo Biosciences located?

Artelo Biosciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von Artelo Biosciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Artelo Biosciences from 11/12/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/12/2024.

When did Artelo Biosciences pay the last dividend?

The last dividend was paid out on 11/12/2024.

What was the dividend of Artelo Biosciences in the year 2023?

In the year 2023, Artelo Biosciences distributed 0 USD as dividends.

In which currency does Artelo Biosciences pay out the dividend?

The dividends of Artelo Biosciences are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Artelo Biosciences

Our stock analysis for Artelo Biosciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Artelo Biosciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.